Biomerica in campaign against colorectal cancer:
This article was originally published in Clinica
Executive Summary
Some 17,000 EZ-Detect occult blood tests have been bought from Biomerica as part of the company's month-long colorectal screening campaign, which it is carrying out in Mississippi with Familymeds Pharmacy. The Newport Beach, California-based company has conducted similar campaigns in Philadelphia, Detroit, Baltimore and Hartford. "We are making considerable headway in establishing the role of EZ Detect in combating the nation's number two cancer killer, colorectal cancer," said Francis Capitiano, president of Biomerica's diagnostics division. "These colorectal screening campaigns have become a significant source of revenue for our company," he added.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.